Switching - null sWR [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-05-04 16:04 (5524 d 16:32 ago) – Posting: # 5284
Views: 36,545

Dear Dave, dear All,

❝ One thing I was happy about with the FDA progesterone recommendations was that the FDA specified 0.294 for sig_wr, because a few of their previous publications recommended using 0.25, which didn't map close to the 30% intraCV cutoff.


Please note sigmaS=0.294 is only the switching variability i.e. from which on the scaled ABE criterion is allowed if sWR>sigmaS. In their SAS code the regulatory constant s0 is still 0.25.
See f.i. on page 6 and 8 of the progesterone draft guidance:
  theta=((log(1.25)/0.25)**2
(=0.89257422)

This leads to the discontinuity at CV=30% and the inflation of the consumer's risk around CV=30% as described by:
L. Endrenyi and L. Tothfalusi
"Regulatory Conditions for the Determination of Bioequivalence of Highly Variable Drugs"
J. Pharm. Pharmaceut. Sci. (www.cspsCanada.org) 12 (1): 138 - 149, 2009


Edit: online resource added. [Helmut]

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
25 visitors (0 registered, 25 guests [including 7 identified bots]).
Forum time: 08:36 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5